Eggener Scott E, Carver Brett S, Loeb Stacy, Kondagunta G Varuni, Bosl George J, Sheinfeld Joel
Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Cancer. 2007 Feb 1;109(3):528-35. doi: 10.1002/cncr.22440.
Postchemotherapy surgery is an essential component in the management of patients with metastatic germ cell tumors (GCT). The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT.
By analyzing the institutional prospective surgical database from 1989 to 2004, 71 patients were identified who underwent RPLND after multiple chemotherapy regimens. Clinicopathologic and treatment trends were characterized, and predictors of disease-specific survival (DSS) were evaluated.
The histologic findings at RPLND were fibrosis in 36 men (51%), GCT in 20 men (28%), and teratoma in 15 men (21%). Patients who underwent RPLND from 1989 to 1998 (n = 47), compared with patients who underwent RPLND from 1999 to 2004 (n = 24) were more likely to have GCT (36% vs 13%; P = .04). Patients who received taxane-containing chemotherapy regimens as salvage therapy had lower rates of GCT at RPLND (14% vs 42%; P = .01), higher rates of fibrosis (63% vs 39%; P = .04), and similar rates of teratoma (31% vs 33%; P = .9). The 5- and 10-year DSS rates were 74% (95% confidence interval [95% CI], 62-86%) and 70% (95% CI, 56-84%), respectively. Five-year DSS based on worst histology of RPLND and extraretroperitoneal specimens was 87% (95% CI, 75-99%) for fibrosis, 87% for teratoma (95% CI, 63-100%), and 47% for GCT (95% CI, 23-71%; P = .004). On multivariable analysis, retroperitoneal mass > or = 5 cm and GCT were predictors of worse DSS (P = .03 and P = .005, respectively).
Taxane-based salvage chemotherapeutic regimens appear to have decreased the rate of GCT at RPLND. The current data support RPLND in select patients after salvage chemotherapy, because a considerable proportion has teratoma or GCT, and the 10-year DSS rate after resection is 70%.
化疗后手术是转移性生殖细胞肿瘤(GCT)患者治疗的重要组成部分。作者评估了他们机构中晚期GCT患者接受多种化疗方案后进行腹膜后淋巴结清扫术(RPLND)的经验。
通过分析1989年至2004年机构前瞻性手术数据库,确定了71例接受多种化疗方案后进行RPLND的患者。对临床病理和治疗趋势进行了特征描述,并评估了疾病特异性生存(DSS)的预测因素。
RPLND的组织学结果为纤维化36例(51%),GCT 20例(28%),畸胎瘤15例(21%)。1989年至1998年接受RPLND的患者(n = 47)与1999年至2004年接受RPLND的患者(n = 24)相比,更有可能患有GCT(36%对13%;P = 0.04)。接受含紫杉烷化疗方案作为挽救治疗的患者在RPLND时GCT发生率较低(14%对42%;P = 0.01),纤维化发生率较高(63%对39%;P = 0.04),畸胎瘤发生率相似(31%对33%;P = 0.9)。5年和10年DSS率分别为74%(95%置信区间[95%CI],62 - 86%)和70%(95%CI,56 - 84%)。基于RPLND和腹膜后外标本最差组织学的5年DSS率,纤维化患者为87%(95%CI,75 - 99%),畸胎瘤患者为87%(95%CI,63 - 100%),GCT患者为47%(95%CI,23 - 71%;P = 0.004)。多变量分析显示,腹膜后肿块≥5 cm和GCT是DSS较差的预测因素(分别为P = 0.03和P = 0.005)。
基于紫杉烷的挽救化疗方案似乎降低了RPLND时GCT的发生率。目前的数据支持在挽救化疗后对部分患者进行RPLND,因为相当一部分患者患有畸胎瘤或GCT,切除后的10年DSS率为70%。